title: [The effect of interventional therapy in multimodality treatment on multi-drug resistant pulmonary tuberculosis].
abstract: OBJECTIVE
  To evaluate the effect of interventional therapy with antituberculous drug instillation to the lesions in the treatment of multi-drug resistant pulmonary tuberculosis (MDR-PTB) on conventional therapy.
  
  
  METHODS
  Sixty-one cases of MDR TB were included from January 2001 to October 2002 in five hospitals. Pasiniazide, rifapentine levofloxacin, ethambutol, ethionamide, amikacin and clarithromycin were used as the basic chemotherapy regimen. In addition, M. vaccac and interventional therapy were used, and chemotherapy was continued for a total of 18 months.
  
  
  RESULTS
  The sputum negative conversion rate (including sputum smear and culture) was 50.8% (31/61) after 3 months of interventional therapy. The rate increased to 83.6% (51/61) after 18 months of therapy. Chest X-ray showed that, the foci were markedly absorbed in 50.8% (31/61), and the effective rate was 93.4% (57/61) after 3 months of therapy. The foci were markedly absorbed in 78.7% (48/61) after 18 months of treatment. The effective rate was 96.7%. The rate of cavity closure was 21.3% (13/61) after 3 months of interventional therapy and it increased to 49.2% (30/61) after 18 months of treatment. The rate of symptom disappearance was 73.2%-94.4%, including fever, hemoptysis and dyspnea.
  
  
  CONCLUSIONS
  For the treatment of MDR-TB, interventional therapy is effective in improving sputum negative conversion, lesion absorption and cavity closure.
authors.affiliation: Department of Tuberculosis, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Fu
authors.forename: Nai-Hui
authors.initials: NH
authors.lastname: Chu
authors.forename: Song-Lin
authors.initials: SL
authors.lastname: Yuan
authors.forename: Wei
authors.initials: W
authors.lastname: Chen
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
authors.forename: Yong-Ai
authors.initials: YA
authors.lastname: Luo
authors.forename: He-Ping
authors.initials: HP
authors.lastname: Xiao
authors.forename: Li-Zhen
authors.initials: LZ
authors.lastname: Zhu
mesh_terms: D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D016896:Treatment Outcome; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents